Genenta Science S.p.A (GNTA) Net Equity Issued and Repurchased (2024 - 2025)
Genenta Science S.p.A (GNTA) posted Net Equity Issued and Repurchased of -$34038.0 for Q2 2025, down 27385.03% sequentially from -$123.84 in Q2 2024, and down 27385.03% YoY from N/an in Q2 2024.
Genenta Science S.p.A (GNTA) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at -$34038.0 in Q2 2025.
- Quarterly Net Equity Issued and Repurchased fell 27385.03% year-over-year to -$34038.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$34161.9 (changed N/A YoY) and the FY2025 annual result came in at $17.2 million, up 5846.54% from the prior year.
- Net Equity Issued and Repurchased declined to -$34038.0 in Q2 2025 per GNTA's latest filing, from -$123.84 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at -$123.84 in Q2 2024 and troughed at -$34038.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -34,038.03 |
| Jun 30, 2025 | -34,038.03 |
| Jun 30, 2024 | -123.84 |
| Jun 30, 2024 | -123.84 |